Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CytomX Therapeutics Inc. CTMX

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platform. The company probody technology platform to create proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting...


Recent & Breaking News (NDAQ:CTMX)

CytomX Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire 6 days ago

CytomX Therapeutics to Present at Upcoming Virtual August Investor Conferences

GlobeNewswire 8 days ago

CytomX Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022

GlobeNewswire July 28, 2022

CytomX Therapeutics Provides Strategic Update

GlobeNewswire July 13, 2022

CytomX Therapeutics Announces Phase 2 Results for Praluzatamab Ravtansine in Breast Cancer

GlobeNewswire July 6, 2022

CytomX Therapeutics Announces New Employment Inducement Grants

GlobeNewswire June 16, 2022

CytomX Therapeutics to Present at Jefferies 2022 Global Healthcare Conference

GlobeNewswire June 1, 2022

CytomX Therapeutics Announces First Patient Dosed with CX-904 in Phase 1 Study in Patients with Advanced Solid Tumors

GlobeNewswire May 26, 2022

CytomX Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire May 5, 2022

CytomX Therapeutics to Report First Quarter 2022 Financial Results on May 5, 2022

GlobeNewswire April 28, 2022

CytomX Therapeutics Announces Retirement of John A. Scarlett, M.D. from Board of Directors

GlobeNewswire April 14, 2022

CytomX Therapeutics Announces Retirement of Frederick W. Gluck from Board of Directors

GlobeNewswire March 23, 2022

CytomX Therapeutics to Present Updated Preclinical Data for Conditionally Activated Cytokine Program at AACR Annual Meeting 2022

GlobeNewswire March 17, 2022

CytomX Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Business Update

GlobeNewswire March 1, 2022

CytomX Therapeutics to Present at Cowen 42nd Annual Healthcare Conference

GlobeNewswire February 28, 2022

CytomX Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022

GlobeNewswire February 22, 2022

CytomX Therapeutics Announces New Employment Inducement Grants

GlobeNewswire February 16, 2022

CytomX Therapeutics Announces Promotion of Amy C. Peterson, M.D. to President and Chief Operating Officer

GlobeNewswire February 7, 2022

CytomX Therapeutics Announces New Employment Inducement Grants

GlobeNewswire January 20, 2022

CytomX Therapeutics Announces FDA Clearance of Investigational New Drug Application for CX-904 for the Treatment of Advanced Solid Tumors

GlobeNewswire January 19, 2022